FROM:
Description
BiVictriX Therapeutics Ltd (“BVX”) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX’s first-in-class Bi-Cygni® bispecific Antibody Drug Conjugates (“ADCs”) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.
READ MORE >
Company Snapshot
Status
Live
Dealing Restrictions
None
Price
11.50
Ticker
BVX
Class
Ord
Settlement
CREST
Industry
Professional, scientific & technical services
COUNTRY
United Kingdom
Company Number
10005270
ISIN
GB00BNXH3K91
Currency
GBX
COMPANY INSIGHTS
Incorporated
15 February 2016
Securities in Issue
82,526,088
Market Cap
£9.08M
Trading Results
| Date | Quantity | Mid. Price GBX |
|---|---|---|
| 18/10/2024 | 48,282 | 10.50 |
| 30/09/2024 | 50,000 | 11.50 |
| 16/09/2024 | 100,000 | 11.00 |
| 16/09/2024 | 150,000 | 11.00 |
key features of trading on jp jenkins
BUYERS
Buyers decide on the price per share they’re willing to pay, and the number of shares they wish to buy.
SELLERS
Sellers decide the minimum price they’ll accept for their shares.
IMPORTANT INFORMATION
This instruments from BIVICTRIX THERAPEUTICS PLC is not traded on an investment exchange such as the London Stock Exchange or the Alternative Investment Market. Consequently, transactions involving these instruments may be infrequent, potentially causing a delay between when you give instructions to buy or sell and when your order is executed. Additionally, it can be challenging to accurately assess the value of your investment.
Download Area
Description
BiVictriX Therapeutics Ltd (“BVX”) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX’s first-in-class Bi-Cygni® bispecific Antibody Drug Conjugates (“ADCs”) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.
READ MORE >
Latest News
SEE MORE NEWS ARTICLES >
BIVICTRIX THERAPEUTICS PLC Management Information
BIVICTRIX THERAPEUTICS PLC Contact Details
Address
Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG
EMAIL
info@bivictrix.com
phone
Contacts
Registrar
Share Registrars Limited
The Courtyard
17 West Street
Farnham
Surrey GU9 7DR
The Courtyard
17 West Street
Farnham
Surrey GU9 7DR
TRANSACTING ON JP JENKINS
‘Trading‘ on JP Jenkins is done via a matched bargain facility, this means that on instruction from your ‘Broker’ we will endeavour to match your shares against other buyer(s) or seller(s) who are also looking to transact. Requests to trade are performed on an availability basis, should an instruction be cancelled, altered or amended in anyway by an instruction from your broker then it shall lose its active place in the queue and reset to the end of list. JP Jenkins receives orders from brokers electronically via a FIX message or should your broker not have a FIX connection to our platform via telephone. If you do not have a UK registered stockbroker you will find a list of brokers that we have worked with to download here. You will also find a list of UK brokers at the bottom of this page and their contact details should you need to appoint one. JP Jenkins can ONLY take instruction to transact from a UK-registered stockbroker and cannot offer investment advice into companies displayed on our website. If you are unsure about trading please consult a financial advisor or wealth manager to assist you in determining what is right for you
